These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1119 related articles for article (PubMed ID: 10570751)

  • 1. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation.
    Krup OC; Kroll I; Böse G; Falkenberg FW
    J Immunother; 1999 Nov; 22(6):525-38. PubMed ID: 10570751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for gene-transfected tumor cells.
    Koppenhagen FJ; Küpcü Z; Wallner G; Crommelin DJ; Wagner E; Storm G; Kircheis R
    Clin Cancer Res; 1998 Aug; 4(8):1881-6. PubMed ID: 9717815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines.
    van Slooten ML; Storm G; Zoephel A; Küpcü Z; Boerman O; Crommelin DJ; Wagner E; Kircheis R
    Pharm Res; 2000 Jan; 17(1):42-8. PubMed ID: 10714607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines.
    Nishisaka N; Maini A; Kinoshita Y; Yasumoto R; Kishimoto T; Jones RF; Morse P; Hillman GG; Wang CY; Haas GP
    J Immunother; 1999 Jul; 22(4):308-14. PubMed ID: 10404432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomes as cytokine-supplement in tumor cell-based vaccines.
    van Slooten ML; Kircheis R; Koppenhagen FJ; Wagner E; Storm G
    Int J Pharm; 1999 Jun; 183(1):33-6. PubMed ID: 10361150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
    Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.
    Fenton RG; Steis RG; Madara K; Zea AH; Ochoa AC; Janik JE; Smith JW; Gause BL; Sharfman WH; Urba WJ; Hanna MG; DeJager RL; Coyne MX; Crouch RD; Gray P; Beveridge J; Creekmore SP; Holmlund J; Curti BD; Sznol M; Longo DL
    J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):364-74. PubMed ID: 8941876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of GM-CSF signaling in cell-based tumor immunization.
    Zarei S; Schwenter F; Luy P; Aurrand-Lions M; Morel P; Kopf M; Dranoff G; Mach N
    Blood; 2009 Jun; 113(26):6658-68. PubMed ID: 19282460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of interleukin-2 entrapped in liposomes on murine renal cell carcinoma.
    Oya M
    Keio J Med; 1994 Mar; 43(1):37-44. PubMed ID: 8189679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
    Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
    Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
    Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
    Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of irradiated renal carcinoma expressing hepatitis B surface antigen against renal-cell carcinoma-mediated tumors.
    Moon Y; Cho SG; Lee JW; Min WS; Kim CC; Lee HK; Kim YG; Chang HS; Chae HS; Kim HY; Tani K
    Cancer Biother Radiopharm; 2006 Jun; 21(3):211-6. PubMed ID: 16918297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
    Dranoff G; Jaffee E; Lazenby A; Golumbek P; Levitsky H; Brose K; Jackson V; Hamada H; Pardoll D; Mulligan RC
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3539-43. PubMed ID: 8097319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O; Dohlsten M; Sjögren HO
    Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
    Chang AE; Li Q; Jiang G; Sayre DM; Braun TM; Redman BG
    J Clin Oncol; 2003 Mar; 21(5):884-90. PubMed ID: 12610189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
    Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
    J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of cytokine drug delivery systems to the immunotherapy of renal cell carcinoma in mice.
    Marumo K; Oya M; Murai M; Tazaki H
    Int J Urol; 1996 Jan; 3(1 Suppl):S24-7. PubMed ID: 24304015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
    Rakhmilevich AL; Buhtoiarov IN; Malkovsky M; Sondel PM
    Cancer Immunol Immunother; 2008 Aug; 57(8):1151-60. PubMed ID: 18214476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.